Kailera Therapeutics, Inc.

Filing Date

Apr 16, 2026

Transaction Date

Apr 16, 2026

Accession Number

0001829126-26-003567

Form Type

3

Footnotes

1. (F1)The Series B Preferred Stock, par value $0.00001 per share, of the Issuer is convertible into shares of the Issuer's common stock, par value $0.00001 per share, on a one-for-one basis and will mandatorily convert into Common Stock upon the closing of the Issuer's initial public offering.
2. (F2)The securities reported herein are held directly by The Stuart Partners, LLC. SP Investment Associates, LLC, a Delaware limited liability company, is the sole member and manager of The Stuart Partners, LLC and has voting and dispositive power over such securities. The Manager of SP Investment Associates, LLC is Roundview Partners, LLC, which may be deemed to share voting and dispositive power over the securities held by The Stuart Partners, LLC. Roundview Partners, LLC's Manager, Anastasios Parafestas, may be deemed to share voting and dispositive power over the securities held by The Stuart Partners, LLC. All such parties disclaim beneficial ownership of the securities reported herein except to the extent of their pecuniary interest therein.